Tenaya Therapeutics ( (TNYA) ) has provided an update.
On March 3, 2025, Tenaya Therapeutics announced the pricing of its public offering of 75 million units, expected to generate approximately $52.5 million in gross proceeds. The funds will support the development of clinical and early-stage product candidates, including TN-201 and TN-401, and general corporate purposes. The offering, managed by Leerink Partners and Piper Sandler, is anticipated to close on March 5, 2025, subject to customary conditions.
More about Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease. The company utilizes integrated capabilities such as target validation, capsid engineering, and manufacturing to create genetic medicines for rare genetic disorders and prevalent heart conditions. Its pipeline includes gene therapies like TN-201 for hypertrophic cardiomyopathy and TN-401 for arrhythmogenic right ventricular cardiomyopathy, among others.
YTD Price Performance: -28.87%
Average Trading Volume: 3,518,733
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $80.01M
For detailed information about TNYA stock, go to TipRanks’ Stock Analysis page.